Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 2/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346896 | 0.86 | KDM4E (0.33) | MCHR1GPR183SRD5A2OGA | |
| SCHEMBL12128813 | 0.84 | ABCB1 (0.43) | XDHEGFR | |
| SCHEMBL6392741 | 0.80 | OGA (0.51) | EGFROGA | |
| SCHEMBL5211605 | 0.75 | HSD11B1 (0.49) | XDHSRD5A2 | |
| SCHEMBL14720788 | 0.74 | SRD5A2 (0.48) | MCHR1GPR183SRD5A2 | |
| SCHEMBL4714589 | 0.74 | HTT (0.40) | SRD5A2 | |
| SCHEMBL1011235 | 0.73 | FAAH (0.55) | — | |
| SCHEMBL1896056 | 0.73 | EPHX2 (0.45) | — | |
| SCHEMBL11956985 | 0.72 | GCK (0.40) | — | |
| SCHEMBL11949134 | 0.72 | XDH (0.38) | XDHEGFRNFE2L2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8557998-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8232405-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8063223-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2239254-A1 | BENZYLPIPERIZINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | XDH 539/4885EGFR 4239/4885NFE2L2 718/4885 |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | XDH 539/4885EGFR 4239/4885NFE2L2 718/4885 |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | XDH 539/4885EGFR 4239/4885NFE2L2 718/4885 |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | XDH 539/4885EGFR 4239/4885NFE2L2 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.